1.00

0.99% -0.01

Pre-market: 1.02 0.02 +2.00%

Actinium Pharmaceuticals Inc (ATNM)

Overview News Price History Option Chain Discussions Forecast Stock Split

Actinium Pharmaceuticals Inc stock is traded at $1.00, with a volume of 101.56K. It is down -0.99% in the last 24 hours and down -20.00% over the past month. Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Previous Close:

$1.01

Open:

24h Volume:

101.56K

Relative Volume:

0.57

Market Cap:

$31.37M

Revenue:

$90,000

Net Income/Loss:

$-23.47M

P/E Ratio:

-1.3294

EPS:

-0.7522

Net Cash Flow:

$-22.98M

1W Performance:

-5.66%

1M Performance:

-20.00%

6M Performance:

-37.11%

1Y Performance:

-32.89%

1-Day Range:

$1.00

$1.03

1-Week Range:

$1.00

$1.10

52-Week Range:

$0.952

$1.89

Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile

Name

Actinium Pharmaceuticals Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

646-767-3870

Address

275 Madison Avenue, 7th Floor, New York, NY

Employee

Twitter

@actiniumpharma

Next Earnings Date

2026-05-08

Latest SEC Filings

ATNM's Discussions on Twitter

Compare ATNM vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATNM Actinium Pharmaceuticals Inc	1.00	31.37M	90,000	-23.47M	-22.98M	-0.7522
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-07-24	Downgrade	B. Riley Securities	Buy → Neutral
May-14-24	Initiated	Stephens	Overweight
Sep-06-23	Initiated	HSBC Securities	Buy
Feb-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-08-22	Initiated	Cantor Fitzgerald	Overweight
Aug-25-22	Initiated	B. Riley Securities	Buy
Nov-05-20	Initiated	Alliance Global Partners	Buy
Dec-06-17	Initiated	B. Riley FBR, Inc.	Buy
Oct-23-17	Resumed	ROTH Capital	Buy
Sep-14-17	Initiated	Maxim Group	Buy
Aug-25-16	Initiated	ROTH Capital	Buy
Feb-29-16	Initiated	H.C. Wainwright	Buy
Oct-15-15	Initiated	FBR Capital	Outperform
Oct-01-14	Initiated	MLV & Co	Buy
Jul-22-14	Initiated	Canaccord Genuity	Buy

View All

Actinium Pharmaceuticals Inc Stock (ATNM) Latest News

Jun 12, 2026

ATNM Should I Buy - Intellectia AI

Jun 12, 2026

Jun 05, 2026

Actinium Pharmaceuticals presents expanded ATNM-400 results in NSCLC and prostate cancer - Traders Union

Jun 05, 2026

Jun 04, 2026

Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC - BioWorld News

Jun 04, 2026

Actinium presents preclinical data on ATNM-400 for lung cancer - Investing.com UK

Jun 04, 2026

Jun 03, 2026

Actinium Pharmaceuticals (ATNM) Reveals Promising Preclinical Data for NSCLC Treatment - GuruFocus

Jun 03, 2026

Actinium presents preclinical data on ATNM-400 for lung cancer By Investing.com - Investing.com Australia

Jun 03, 2026

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer - PR Newswire

Jun 03, 2026

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models - PR Newswire

Jun 03, 2026

Jun 01, 2026

Actinium Pharmaceuticals (ATNM) Appoints New Chief Medical Officer - GuruFocus

Jun 01, 2026

Actinium Pharmaceuticals (ATNM) Unveils Key Radiochemistry Findi - GuruFocus

Jun 01, 2026

Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development - PR Newswire

Jun 01, 2026

Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates - PR Newswire

Jun 01, 2026

May 31, 2026

Actinium Pharmaceuticals Presents ATNM-400 Program Updates at SNMMI 2026 and Addresses NYSE American Listing Compliance Notice - Minichart

May 31, 2026

May 30, 2026

Actinium Pharmaceuticals Advances with Canadian Patent Allowances for ATNM - GuruFocus

May 30, 2026

May 29, 2026

Actinium Highlights New ATNM-400 Data Amid Listing Pressure - TipRanks

May 29, 2026